Amgen Inc.

Sage Therapeutics, Inc.

Daniel La

Matthew M Weiss

Russell Graceffa

Vinod Francis Patel

Francesco Gerald Salituro

Albert Jean Robichaud

Boyd Lynn Harrison

Craig E Masse

Patricia Lopez

Wenge Zhong

Yuan Cheng

Gabriel Martinez Botella

Brian K Albrecht

Stephen A Hitchcock

Holger Monenschein

Thomas T Nguyen

Matthew R Kaller

Qiufen May Xue

Andrew Mark Griffin

Scott S Harried

Ted Charles Judd

Michael D Bartberger

James A Brown

Ning Xi

Jean-Christophe P Harmange

Shon Booker

Steven F Bellon

Hanh Nho Nguyen

Tae-Seong Kim

Celia Dominguez

Matthew W Martin

Andrew Stewart Tasker

David Craig McGowan

Joseph L Kim

Mark Henry Norman

Brian Lewis Hodous

Longbin Liu

Kevin Chao Yang

Shimin Xu

Angel Guzman-Perez

Aaron C Siegmund

Lucian V DiPietro

Jian Jeffrey Chen

Qingyian Liu

Nobuko Nishimura

Ryan D White

Albert Kudzovi Amegadzie

Vu Van Ma

Qi Huang

Chester Chenguang Yuan

Daniel B Horne

Alan C Cheng

Markian Myroslaw Stec

Charles Kreiman

Stuart C Chaffee

Alessandro Boezio

Isaac E Marx

Lewis D Pennington

Thomas Nixey

Randall W Hungate

Bryant Yang

Thomas Dineen

Michael D Croghan

Julie Germain

Erin F DiMauro

Deborah Choquette

Michele Potashman

Emily Anne Peterson

John R Butler

Hongbing Huang

Joseph J Nunes

Derin C D'amico

John Laird Buchanan

Noel D'Angelo

Matthew Lee

David Bauer

Howard Bregman

Wenyuan Qian

Gwenaella Rescourio

Benny C Askew

Karina Romero

Aiwen Li

Maria Jesus Blanco-Pillado

Gregory J Habgood

Nagasree Chakka

Benjamin Charles Milgram

Ingrid M Fellows

George Borg

Philip M Roveto

Jason Brooks Human

Philip R Olivieri

Vijay Keshav Gore

Zihao Hua

Holly L Deak

Oleg Epstein

Bingfan Du

Marian C Bryan

John Stellwagen

Babak Riahi

Thomas Storz

Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

Compositions and methods for treating CNS disorders

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, n, R, R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

C7 substituted oxysterols and methods of use thereof

Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, Rand R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. 

Oxysterols and methods of use thereof

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, n, R, R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. 

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, R, and R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. 

The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Pyridine sulfonamides

The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic sulfonamide compounds as sodium channel inhibitors

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.  The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic aryl and heteroaryl sodium channel inhibitors

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Method of treating cancer with substituted amide derivatives

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, T, T, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use

Compounds and methods of use

Growing community of inventors

Brookline, MA, United States of America

Daniel La